Biotech Values

[DewDiligence]

TEVA ELN BIIB MNTA: See page 9 of the transcript of the [Teva] call.

This may be a case where it’s important to listen to the call rather than reading the transcript, where you lose some contextual cues. To reiterate, I thought it was clear from the context that the pricing comment we’re discussing referred to Tysabri, so we’ll have to agree to disagree on this narrow question.

The larger point in this thread on Copaxone vs Tysabri is that you seem to think sales growth that stems from pricing is somehow worth much less than sales growth that stems from volume. All else being equal, I’d rather see growth from volume than from price, but this is a matter of degree and I think you overstate your case. Money, after all, is fungible.